Article content
Sex monster Jeffrey Epstein plotted his seduction of the billionaire founder of Victoria’s Secret with military precision, according to a new report.
Vanity Fair reports that hedge fund manager Epstein weaseled his way into the lingerie giant’s inner circle by way of pal Robert Meister.
We apologize, but this video has failed to load.
Try refreshing your browser, or How bulls t artist Jeffrey Epstein seduced Victoria s Secret CEO Back to video
“He was a great bulls t artist,” Meister told the glossy mag, adding that he believes Epstein befriended him in order to gain access to his billionaire pals.
Business Development Executive in Biologics Drug Development and Manufacturing Brings More than 25 Years of Biopharmaceutical Industry Experience Selexis SA, a JSR Life Sciences company, has named
GENEVA (BUSINESS WIRE) Jun 1, 2021
Selexis SA, a JSR Life Sciences company, has named seasoned business development executive Roland Hoffmann-Hecht, PhD, as its new chief business officer. As a member of the companyâs executive leadership team, Dr. Hoffmann-Hecht will be responsible for all corporate and business development activities and will report directly to Selexis Chief Executive Officer Dirk Lange.
(Photo: Business Wire)
âWe are fortunate to welcome Roland to our executive leadership team given his expansive career in contract development and manufacturing organizations (CDMOs) serving the biopharmaceuticals industry and demonstrated success building valuable relationships with partners,â said Mr. Lange. âHis highly relevant skills and experience, coupled with his scientific and industry knowledge, will be invaluable to Selexis as we bolster our leading position in cell line development and ensure the continued success of our âGene-to-GMP in 9 Mon
Selexis SA, a JSR Life Sciences company, announced today that Great Place to Work has designated the Company among the "Best Workplaces Switzerland" in 2021. Selexis joins companies across a broad
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Myconic Capital Announces Closing of Mindscape Ketamine & Infusions Therapy Acquisition
MYCONIC CAPITAL CORP.April 22, 2021 GMT
VANCOUVER, British Columbia, April 21, 2021 (GLOBE NEWSWIRE) Myconic Capital Corp. (formerly, Auralite Investments Inc.) (CSE: MEDI) (FRA: MY0) (the “Company” or “Myconic”) is pleased to announce that, further to its press release of March 10, 2021, it has completed the acquisition of all of the issued and outstanding equity of Mindscape Ketamine & Infusions Therapy, PLLC (“Mindscape”) a mental health and pain clinic based in Houston, Texas. As a result, Myconic made a cash payment of US$50,000 and issued 94,292 common shares of Myconic (the “Payment Shares”) to the sole owner of Mindscape.